Get the Stockscreener App
2.28
1.72%
-0.04
After Hours:
2.28
Oramed Pharmaceuticals Inc stock is traded at $2.28, with a volume of 137.56K.
It is down -1.72% in the last 24 hours and down -2.98% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.32
Open:
$2.32
24h Volume:
137.56K
Relative Volume:
0.94
Market Cap:
$91.91M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
20.73
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-4.60%
1M Performance:
-2.98%
6M Performance:
-11.28%
1Y Performance:
+4.59%
1-Day Range:
$2.27
$2.36
1-Week Range:
$2.27
$2.41
52-Week Range:
$2.00
$3.67
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.28 | 91.91M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.com - MarketBeat
Oramed Pharmaceuticals Reports Deferral and Consent Agreement for Tranche B Senior Secured Convertible Note - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to Sell Rating by StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
ADVANZ PHARMA (OTCMKTS:CXRXF) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to “Hold” - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Hold at StockNews.com - MarketBeat
Oramed secures $13.2 million payment from Scilex - Investing.com
Oramed secures $13.2 million payment from Scilex By Investing.com - Investing.com UK
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC - MarketBeat
Oramed Pharmaceuticals : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTSAS OF SEPTEMBER 30, 2024 - Marketscreener.com
Type 1 Diabetes Market Future Business Opportunities 2024-2031 - openPR
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Oramed Announces Additional $1M Payment on Tranche A Note By Investing.com - Investing.com South Africa
Oramed Announces Additional $1M Payment on Tranche A Note - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com - MarketBeat
ORAMED PHARMACEUTICALS INC. Refinances with New Securities Purchase Agreement - MarketBeat
Oramed Pharmaceuticals Reinforces Scilex Financial Ties - TipRanks
Scilex Holding extends payment deadline in Oramed agreement - Investing.com India
Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - Marketscreener.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Bought by Murchinson Ltd. - MarketBeat
Oramed signs $11.5 million deal for clinical trial services By Investing.com - Investing.com South Africa
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed - Barchart
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):